Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.

Rituximab treatment for recurrence of nephrotic syndrome in a pediatric patient after renal transplantation for congenital nephrotic syndrome of Finnish type.

Chaudhuri A, Kambham N, Sutherland S, Grimm P, Alexander S, Concepcion W, Sarwal M, Wong C.

Pediatr Transplant. 2012 Aug;16(5):E183-7. doi: 10.1111/j.1399-3046.2011.01519.x. Epub 2011 Jun 15.

PMID:
21672106
2.

Rituximab and chronic plasmapheresis therapy of nephrotic syndrome in renal transplantation patients with recurrent focal segmental glomerulosclerosis.

Rodríguez-Ferrero M, Ampuero J, Anaya F.

Transplant Proc. 2009 Jul-Aug;41(6):2406-8. doi: 10.1016/j.transproceed.2009.06.044.

PMID:
19715934
3.

Long-term effect of rituximab in maintaining remission of recurrent and plasmapheresis-dependent nephrotic syndrome post-renal transplantation - case report.

Grenda R, Jarmużek W, Piątosa B, Rubik J.

Pediatr Transplant. 2011 Sep;15(6):E121-5. doi: 10.1111/j.1399-3046.2010.01303.x. Epub 2010 Mar 16.

PMID:
20331516
4.

Congenital nephrotic syndrome and recurrence of proteinuria after renal transplantation.

Holmberg C, Jalanko H.

Pediatr Nephrol. 2014 Dec;29(12):2309-17. doi: 10.1007/s00467-014-2781-z. Epub 2014 Mar 29. Review.

5.

Recurrence of proteinuria following renal transplantation in congenital nephrotic syndrome of the Finnish type.

Srivastava T, Garola RE, Kestila M, Tryggvason K, Ruotsalainen V, Sharma M, Savin VJ, Jalanko H, Warady BA.

Pediatr Nephrol. 2006 May;21(5):711-8. Epub 2006 Mar 4.

PMID:
16518627
6.

Plasma exchange and retransplantation in recurrent nephrosis of patients with congenital nephrotic syndrome of the Finnish type (NPHS1).

Kuusniemi AM, Qvist E, Sun Y, Patrakka J, Rönnholm K, Karikoski R, Jalanko H.

Transplantation. 2007 May 27;83(10):1316-23.

PMID:
17519780
7.

Recurrence of nephrotic syndrome in kidney grafts of patients with congenital nephrotic syndrome of the Finnish type: role of nephrin.

Patrakka J, Ruotsalainen V, Reponen P, Qvist E, Laine J, Holmberg C, Tryggvason K, Jalanko H.

Transplantation. 2002 Feb 15;73(3):394-403.

PMID:
11884936
8.

Rituximab for refractory cases of childhood nephrotic syndrome.

Kari JA, El-Morshedy SM, El-Desoky S, Alshaya HO, Rahim KA, Edrees BM.

Pediatr Nephrol. 2011 May;26(5):733-7. doi: 10.1007/s00467-011-1778-0. Epub 2011 Jan 31.

PMID:
21279725
9.

Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood--follow-up after CD19 recovery.

Sellier-Leclerc AL, Baudouin V, Kwon T, Macher MA, Guérin V, Lapillonne H, Deschênes G, Ulinski T.

Nephrol Dial Transplant. 2012 Mar;27(3):1083-9. doi: 10.1093/ndt/gfr405. Epub 2011 Aug 1.

10.

Critical evaluation of rituximab rescue in 27 patients with different types of kidney disease.

Ganzemueller J, Hartmann B, Keller F, Stracke S.

Minerva Urol Nefrol. 2011 Dec;63(4):263-72.

PMID:
21996981
11.

Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome.

Ito S, Kamei K, Ogura M, Udagawa T, Fujinaga S, Saito M, Sako M, Iijima K.

Pediatr Nephrol. 2013 Feb;28(2):257-64. doi: 10.1007/s00467-012-2319-1. Epub 2012 Oct 10.

PMID:
23052656
12.

Immediate post-transplant nephrosis in a patient with congenital nephrotic syndrome.

Barayan SS, Al-Akash SI, Malekzadeh M, Marik JL, Cohen AH, Ettenger RB, Yadin O.

Pediatr Nephrol. 2001 Jul;16(7):547-9.

PMID:
11465801
13.

Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome.

Kemper MJ, Gellermann J, Habbig S, Krmar RT, Dittrich K, Jungraithmayr T, Pape L, Patzer L, Billing H, Weber L, Pohl M, Rosenthal K, Rosahl A, Mueller-Wiefel DE, Dötsch J.

Nephrol Dial Transplant. 2012 May;27(5):1910-5. doi: 10.1093/ndt/gfr548. Epub 2011 Nov 9.

14.

Rituximab in steroid-dependent nephrotic syndrome.

El Koumi M.

Iran J Kidney Dis. 2013 Nov;7(6):502-6.

15.

New therapies in steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome.

van Husen M, Kemper MJ.

Pediatr Nephrol. 2011 Jun;26(6):881-92. doi: 10.1007/s00467-010-1717-5. Epub 2011 Jan 13. Review.

PMID:
21229269
16.

[Treatment of children with steroid-dependent nephrotic syndrome with rituximab].

Huang J, Du J, Wang S, Xiao L, Zhao X.

Zhonghua Er Ke Za Zhi. 2014 Jul;52(7):521-4. Chinese.

PMID:
25224058
17.

Serum glomerular permeability activity in patients with podocin mutations (NPHS2) and steroid-resistant nephrotic syndrome.

Carraro M, Caridi G, Bruschi M, Artero M, Bertelli R, Zennaro C, Musante L, Candiano G, Perfumo F, Ghiggeri GM.

J Am Soc Nephrol. 2002 Jul;13(7):1946-52.

18.

Pretransplantation combined therapy with plasmapheresis and rituximab in a second living-related kidney transplant pediatric recipient with a very high risk for focal segmental glomerulosclerosis recurrence.

Chikamoto H, Hattori M, Kuroda N, Kajiho Y, Matsumura H, Fujii H, Ishizuka K, Hisano M, Akioka Y, Nozu K, Kaito H, Shimizu M.

Pediatr Transplant. 2012 Nov;16(7):E286-90. doi: 10.1111/j.1399-3046.2011.01610.x. Epub 2011 Nov 30.

PMID:
22129369
19.

New insights into the pathophysiology of idiopathic nephrotic syndrome.

Bruneau S, Dantal J.

Clin Immunol. 2009 Oct;133(1):13-21. doi: 10.1016/j.clim.2009.03.532. Epub 2009 May 1. Review.

PMID:
19410518
20.

Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome.

Sinha A, Bhatia D, Gulati A, Rawat M, Dinda AK, Hari P, Bagga A.

Nephrol Dial Transplant. 2015 Jan;30(1):96-106. doi: 10.1093/ndt/gfu267. Epub 2014 Aug 13.

PMID:
25121488
Items per page

Supplemental Content

Write to the Help Desk